Abstract
The development over the past few years has shown that gene therapy has become a true perspective. By January 1994, 63 clinical gene therapy protocols (gene therapy or marker studies) have been reviewed and most approved by U.S. control committees. Of these, 13 aim at inserting and expressing cytokine genes in tumor cells in order to use such gene-modified cells as vaccines in cancer patients, This idea is based on mouse experimental models that showed that tumor cells transfected with a variety of cytokine genes were rejected in immunocompetent animals. Tumor rejection induced by the locally produced cytokine results from an inflammatory response at the tumor site. Several observations are remarkable: the high efficacy of local cytokines to induce an antitumor response in the absence of systemic toxicity; a surprisingly large number of cytokines possess antitumor activity in this assay (IL-1, IL-2, IL-4, IL-6, IL-7, TNF, LT, IFN-γ, MCAF, G-CSF, GM-CSF, IP-10); and in several models, cytokine-producing tumors were heavily infiltrated by T-lymphocytes that contributed to tumor destruction (for review see ref. 1). The latter observation is interesting because T-cells can most specifically recognize and destroy tumor cells and are critically involved in tumor immunity Consistently, in several tumor models, mice that were immunized by cytokine-gene transfected tumors also rejected the nontransduced parental tumor and occasionally were able to eliminate small preexisting tumor loads. Tumor immunity was dependent on T-cells. Thus, cytokine gene-modified tumor cell vaccines are thought to trigger a local immune response in cancer patients, which is directed against putative, so far unknown tumor antigens and which are effective against residual (presumably small) tumor loads (e.g., micrometastasis). It is important to note that these genetic approaches to cancer immunotherapy are the beginning of a developing field and still have to address some unresolved problems such as inappropriate presentation of tumor antigens by the tumor cells, tumor-induced immune suppression, tumor heterogeneity, or the question as to whether they are more effective than the previous attempts of immunotherapy. Currently, three cytokine gene therapy variations with IL-2, IL-4, TNF, IFN-γ, or GM-CSF genes are tested: transfected autologous tumor cells; transfected allogeneic tumor cells; and transfected autologous fibroblasts mixed with tumor cells as vaccine. In most cases, the cells are irradiated before injection. Results from these initial clinical trials do not exist yet.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Blankenstein, T. (1994) Increasing tumor immunogenicity by genetic modification. Eur J Cancer 30A, 1182–1187.
Colombo, M. P. and Forni, G. (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15, 48–51.
Gillis, S., Ferm, M. M., Ou, W, and Smith, K. A. (1978) T cell growth factor: parameters of production and a quantitative microassay for activity J. Immunol. 120, 2027–2032.
Palacios, R. and Steimnetz, M. (1985) IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41, 727–734.
Hu-Li, J., Ohara, J., Watson, C., Tsang, W., and Paul, W. E. (1989) Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S) J. Immunol. 142, 800–807.
Rolink, A. G., Melchers, F., and Palacios, R. (1989) Monoclonal antibodies reactive with the mouse interleukin 5 receptor. J. Exp Med 169, 1693–1701.
Van Snick, J., Vink, A., Cayphas, S., and Uyttenhove, C.(1987) Interleukin-HP1, a T cell derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J Exp Med. 165, 641–649.
Park, L. S., Friend, D. J., Schmierer, A. E, Dower, S. K., and Namen, A. E. (1990) Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line J Exp. Med 171, 1073–1089.
Dexter, T. M., Garland, J., Scott, D., Scolnick, E., and Metcalf, D (1980) Growth of factor-dependent hemopoietic precursor cell lines. J Exp. Med. 152, 1036–1047.
Flick, D. A. and Gifford, G. E. (1984) Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol. Meth. 68, 167.
Coligan, J. E., et al. (1992) Current Protocols in Immunology (Coligan, J. E., Kruisbeek, A. M., Marguhes, D. H., Sherach, E. M., and Strober, W., eds), Greene and Wiley, New York, pp. 6.8.3.
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543.
Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamantstein, T., and Blankenstein, T. (1993) Vaccination with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53, 714–716.
Hock, H., Dorsch, M., Kunzendorf, U., Qin, Z., Diamantstein, T, Blankenstein, T. (1993) Mechanisms of rejection induced by tumor cell targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-. Proc. Natl Acad. Sci. USA 90, 2774–2778.
Qin, Z., Krüger-Krasagakes, S., Kunzendorf, U., Hock, H., Diamantstein, T,, and Blankenstein, T. (1993) Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp Med 178, 355–360.
Li, W., Diamantstein, T., and Blankenstein, T. (1990) Lack of tumorigenicity of interleukin 4 autocrme growing cells seems related to the anti-tumor function of interleukin 4. Mol. Immunol 27, 1331–1337.
Blankenstein, T., Qin, Z., Uberla, K., Muller, W., Rosen, H., Volk, H.-D., and Diamantstein, T (1991) Tumor suppression after tumor cell targeted tumor necrosis factor alpha gene transfer, J, Exp Med. 173, 1047–1052
Hock, H., Dorsch, M., Diamantstein, T., and Blankenstein, T (1991) Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med. 174, 1291–1298
Dye, E. S, North, R J., and Mills, C D. (1981) Mechanisms of anti-tumor action of corynebacterium parvum. I. Potential tumor-specific immunity and its therapeutic limitations. J Exp. Med. 154, 609–620.
Oettgen, H F.and Old, L.J (1991) The History of Cancer Immunotherapy (DeVita, V. T., Helman, S., Rosenberg, S. A., eds.), Lippincott, New York, pp, 87–199.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Qin, Z., Blankenstein, T. (1997). Methods for the Use of Cytokine Gene-Modified Tumor Cells in Immunotherapy of Cancer. In: Robbins, P.D. (eds) Gene Therapy Protocols. Methods in Molecular Medicine, vol 7. Humana, Totowa, NJ. https://doi.org/10.1385/0-89603-484-4:339
Download citation
DOI: https://doi.org/10.1385/0-89603-484-4:339
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-0-89603-484-6
Online ISBN: 978-1-59259-591-4
eBook Packages: Springer Protocols